No fragrance, no fillers, no compromises on potency
The participants were divided into the following experimental groups or a placebo group: 1 mg of retatrutide (subcutaneously) 4 mg of retatrutide (subcutaneously), starting at an initial dose of 2 mg 4 mg of retatrutide (subcutaneously), starting at an initial dose of 4 mg 8 mg of retatrutide (subcutaneously), starting at an initial dose of 2 mg 8 mg of retatrutide (subcutaneously), starting at an initial dose of 4 mg 12 mg of retatrutide (subcutaneously), starting at an initial dose of 2 mg Here are the detailed results of the trial at 24 weeks and 48 weeks: Phase II clinical trial projects promising results of retatrutide in weight management
Tissue-related pathway interaction models
Research suggests that optimizing growth hormone levels through Sermorelin may support various aspects of healthy aging including body composition, energy, sleep, skin health, bone density, and metabolic function
[DOI] [PubMed] [Google Scholar] 104.Egecioglu E, Ploj K, Xu X, et al